ALB and neoplasm: The tumor uptake of 177Lu-Alb-L2 and 177Lu-Alb-L3 was significantly lower than our previously reported long-linker-based albumin-binding agent, 177Lu-L14 (Figure 2) (tumor AUC0-192h of 5740 ± 520%ID/g.h), although ≥1.5-fold higher than 177Lu-L1 (tumor AUC0-192h of 1734 ± 130%ID/g.h) (Figure 6A,B) [27].